Trials / Completed

CompletedNCT04526574

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (20VPNC) WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS ≥65 YEARS OF AGE

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 1,796 (actual)

Sponsor: Pfizer · Industry
Sex: All
Age: 65 Years
Healthy volunteers: Accepted

Summary

Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately

Conditions

Pneumococcal Disease

Interventions

Type	Name	Description
BIOLOGICAL	Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)	Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
OTHER	Saline	Normal saline for injection
BIOLOGICAL	Influenza vaccine	Seasonal inactivated influenza vaccine (SIIV)

Timeline

Start date: 2020-09-01
Primary completion: 2021-06-29
Completion: 2021-06-29
First posted: 2020-08-26
Last updated: 2022-07-08
Results posted: 2022-07-08

Locations

63 sites across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04526574. Inclusion in this directory is not an endorsement.